腹部推拿治疗心脾两虚型原发性失眠的脑-肠互动机制研究

注册号:

Registration number:

ITMCTR2100004928

最近更新日期:

Date of Last Refreshed on:

2021-06-09

注册时间:

Date of Registration:

2021-06-09

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

腹部推拿治疗心脾两虚型原发性失眠的脑-肠互动机制研究

Public title:

Study on the brain-gut interaction mechanism of abdominal massage in the treatment of primary insomnia with deficiency of both heart and spleen

注册题目简写:

English Acronym:

研究课题的正式科学名称:

腹部推拿治疗心脾两虚型原发性失眠的脑-肠互动机制研究

Scientific title:

Study on the brain-gut interaction mechanism of abdominal massage in the treatment of primary insomnia with deficiency of both heart and spleen

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

国家自然基金项目资助81574094

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100047158 ; ChiMCTR2100004928

申请注册联系人:

野张

研究负责人:

张红石

Applicant:

Zhang Ye

Study leader:

Zhang Hongshi

申请注册联系人电话:

Applicant telephone:

+86 15714302769

研究负责人电话:

Study leader's telephone:

+86 13943018168

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

735425859@qq.com

研究负责人电子邮件:

Study leader's E-mail:

5503576@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国吉林长春市工农大路1478号

研究负责人通讯地址:

中国吉林长春净月开发区博硕路1035号

Applicant address:

1478 Gongnong Road, Chaoyang District, Changchun, Jilin, China

Study leader's address:

1035 Boshuo Road, Jingyue District, Changchun, Jilin, China

申请注册联系人邮政编码:

Applicant postcode:

130117

研究负责人邮政编码:

Study leader's postcode:

130117

申请人所在单位:

长春中医药大学针灸推拿学院

Applicant's institution:

Department of Acupuncture and Moxibustion, Changchun University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

CCZYFYLL2017审字-051

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

长春中医药大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Affiliated Hospital of Changchun University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2017/8/4 0:00:00

伦理委员会联系人:

高宏伟

Contact Name of the ethic committee:

Gao Hongwei

伦理委员会联系地址:

长春市工农大路1478号

Contact Address of the ethic committee:

1478 Gongnong Road, Chaoyang District, Changchun, Jilin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 431 86177876

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

长春中医药大学护理学院

Primary sponsor:

School of Nursing, Changchun University of Chinese Medicine

研究实施负责(组长)单位地址:

长春净月开发区博硕路1035号长春中医药大学

Primary sponsor's address:

1035 Boshuo Road, Jingyue District, Changchun, Jilin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

吉林

市(区县):

长春

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

长春中医药大学附属医院

具体地址:

工农大路1478号

Institution
hospital:

Affiliated Hospital of Changchun University of Chinese Medicine

Address:

1478 Gongnong Road

经费或物资来源:

国家自然基金项目资助81574094

Source(s) of funding:

National Natural Resources Fund project support 81574054

研究疾病:

失眠

研究疾病代码:

Target disease:

Insomnia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

基于“脑-肠互动”假说,探讨腹部推拿对心脾两虚型原发性失眠患者脑功能核磁及脑肠肽的影响,分析腹部推拿治疗失眠的作用机制。

Objectives of Study:

Based on the hypothesis of “brain-gut interaction”, this paper explores the effects of abdominal massage on the brain function MRI and brain-gut peptides in patients with primary insomnia with deficiency of both the heart and the spleen, and analyzes the mechanism of action of abdominal massage in the treatment of insomnia.

药物成份或治疗方案详述:

本试验采用临床小样本量数字随机对照分组法。由研究者记录受试者基本信息(如出生日期、性别)和回答患者试验筛选问题。患者经筛选确定入组后,由数字随机表抽取随即号进行试验分组,同时患者按入组时间及入组顺序获得试验研究序列号,即患者唯一识别号(SIN),直到完成总观察例数(60例)后结束招募。试验结果共纳入60例患者,按数字随机法,随机分为推拿组(20例)、药物组(20例)、推拿加药物组(20例)。 60例患者入组后分别接受不同的治疗方法。推拿组采用腹部推拿治疗;药物组采用口服人参归脾丸治疗。推拿加药物组采用腹部推拿合用人参归脾丸治疗。

Description for medicine or protocol of treatment in detail:

The clinical small sample size digital randomized control grouping method was used in this study.The investigator records basic subject information (such as date of birth, gender) and answers patient screening questions.After patients were screened and confirmed to be enrolled, random numbers were selected from the digital random table for trial grouping. At the same time, patients were given the serial number of the trial study, i.e. the unique patient identification number (SIN), according to the time and order of enrollment. The recruitment was completed until the total number of observed patients (60 cases) was completed.Results A total of 60 patients were included in the study and randomly divided into massage group (20 cases), drug group (20 cases) and massage plus drug group (20 cases) according to digital random method. Sixty patients received different treatment after enrolment.The massage group was treated with abdominal massage.The drug group was treated with oral ginseng to spleen pills.Massage and medicine group was treated with abdominal massage combined with ginseng guipi pill.

纳入标准:

符合原发性失眠诊断标准及心脾两虚诊断标准,睡眠和觉醒困难不能被其他类型的睡眠障碍更好的解释,同时符合以下9项条件: 1.符合失眠障碍诊断标准,符合心脾两虚型原发性失眠标准。 2.45周岁≤年龄≤65周岁者。 3.未参加其他临床研究者。 4.签署知情同意书,自愿参加本项研究者。 5.匹兹堡睡眠指数(PSQI)指数>7分。 6.阿森斯(AIS)量表积分>6分。 7.抑郁量表(SDS)和焦虑量表(SAS)标准分≤60分者。 8.近2周未服用其它安眠类药物,如果服药需要进行2周药物洗脱。 9.上述症状持续1年以上,频率≥3次/周。

Inclusion criteria

It meets the diagnostic criteria of primary insomnia and deficiency of heart and spleen. Difficulty in sleeping and waking can not be better explained by other types of sleep disorders. Meanwhile, it meets the following 9 conditions: 1. It meets the diagnostic criteria of insomnia disorder and the criteria of primary insomnia with deficiency of heart and spleen; 2. Aged 45 to 65 years; 3. Not participating in other clinical researchers; 4. Signed informed consent and volunteered to participate in this study; 5. Pittsburgh sleep index (PSQI) index >7 points; 6. Athens (AIS) scale score > 6 points; 7. The standard scores of SDS and SAS were <=60; 8. Have not taken other sleeping drugs in the past 2 weeks. If taking drugs, two weeks of drug elution is needed; 9. The above symptoms lasted for more than 1 year with a frequency of >=3 times/week.

排除标准:

1. 患有呼吸相关的睡眠障碍,昼夜节律睡眠障碍和睡眠机能紊乱者; 2. 患全身性疾病,如疼痛、发热、咳嗽等,导致的失眠患者; 3. 合并有心血管、肺、肝、肾和造血系统等严重原发性疾病患者; 4. 精神性疾病患者; 5. 治疗部位皮肤有感染者或皮肤为超敏皮肤; 6. 进展性恶性肿瘤或其它严重消耗性疾病,易合并感染和出血者; 7. 因某种原因,导致无法判断疗效或资料不全等影响疗效和疗效判断者; 8. 由于滥用药物或药物治疗,引起是失眠患者; 9. 由长期过度饮酒、咖啡、浓茶等,及不良生活因素所致的睡眠障碍者; 10. 妊娠或哺乳期妇女。

Exclusion criteria:

1. Insomnia patients due to excessive anxiety, depression, etc.; Breathing related sleep disorders, circadian rhythm sleep disorders, and sleep disorders; 2. Suffer from systemic diseases, such as pain, fever, cough, etc., resulting in insomnia; 3. Patients with cardiovascular, lung, liver, kidney, hematopoietic system and other serious primary diseases; 4. Patients with mental diseases; 5. The skin of the treatment site is infected or the skin is hypersensitive; 6. Progressive malignant tumor or other serious wasting diseases, easy to be complicated with infection and bleeding; 7. For some reason, it is impossible to judge the curative effect or incomplete data affect the curative effect and the judgment of curative effect; 8. Insomnia is caused by drug abuse or medication; 9. Sleep disorders caused by long-term excessive drinking, coffee, strong tea and other adverse living factors; 10. Pregnant or lactating women.

研究实施时间:

Study execute time:

From 2016-01-24

To      2019-12-24

征募观察对象时间:

Recruiting time:

From 2017-08-01

To      2019-08-01

干预措施:

Interventions:

组别:

Group 1

样本量:

20

Group:

Group 1

Sample size:

干预措施:

腹部推拿治疗

干预措施代码:

Intervention:

Massage

Intervention code:

组别:

Group 2

样本量:

20

Group:

Group 2

Sample size:

干预措施:

服用药物

干预措施代码:

Intervention:

Taking drugs

Intervention code:

组别:

Group 3

样本量:

20

Group:

Group 3

Sample size:

干预措施:

推拿+药物治疗

干预措施代码:

Intervention:

Massage and taking drugs

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

吉林

市(区县):

长春

Country:

China

Province:

Jilin

City:

Changchun

单位(医院):

长春中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Affiliated Hospital of Changchun University of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

代谢组学检测

指标类型:

主要指标

Outcome:

1HNMR

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心电图

指标类型:

主要指标

Outcome:

Electrocardiogram

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

去甲肾上腺素

指标类型:

主要指标

Outcome:

Norepinephrine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

皮质醇

指标类型:

主要指标

Outcome:

Cortisol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

促肾上腺皮质激素的释放激素

指标类型:

主要指标

Outcome:

Corticotropin-releasing hormone

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

大脑静息状态的功能性磁共振成像

指标类型:

主要指标

Outcome:

Resting state functional magnetic resonance imaging of the brain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脑肠肽检测

指标类型:

主要指标

Outcome:

Brain intestinal peptide detection

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

5 -羟色胺

指标类型:

主要指标

Outcome:

Serotonin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

γ氨基丁酸酸

指标类型:

主要指标

Outcome:

γ-aminobutyric acid

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

质子波谱分析

指标类型:

主要指标

Outcome:

MRS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

主要指标

Outcome:

PSQI

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

主要指标

Outcome:

Self-Rating Anxiety Scale, SAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评量表

指标类型:

主要指标

Outcome:

Self-Rating Depression Scale, SDS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

前列腺素2

指标类型:

主要指标

Outcome:

Prostaglandin 2

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

促肾上腺皮质激素

指标类型:

主要指标

Outcome:

Adreno-cortico-tropic-hormone

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 44
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本试验采用临床小样本量数字随机对照分组法。由研究者记录受试者基本信息(如出生日期、性别)和回答患者试验筛选问题。患者经筛选确定入组后,由数字随机表抽取随即号进行试验分组,同时患者按入组时间及入组顺序获得试验研究序列号,即患者唯一识别号(SIN),直到完成总观察例数(60例)后结束招募。试验结果共纳入60例患者,按数字随机法,随机分为推拿组(20例)、药物组(20例)、推拿加药物组(20例)。

Randomization Procedure (please state who generates the random number sequence and by what method):

The study investigator will record basic subject information (such as date of birth, gender) and answer patient screening questions.After the patients were screened and confirmed to be enrolled, the serial number of the trial study, i.e. the patient unique identification number (SIN), was obtained according to the&

盲法:

Not stated

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan 临床试验公共管理平台, http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan, http://www.medresman.org.cn.

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan, http://www.medresman.org.cn.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统